At Epi One, much of our most important progress doesn’t happen in headlines — it happens in labs, on calls with clinical partners, and through quiet but deliberate execution.
Over the past six months, we’ve been focused on deepening and expanding our relationships with academic medical centers across the U.S. These partnerships are central to the success of our clinical validation program as we continue developing next-generation PCR assays for the early detection of cancer.
This is thoughtful, methodical work — and it’s beginning to bear fruit. The scientific conversations we’re having, the collaborators we’re engaging, and the mutual commitment to early detection are giving us confidence that the path we’re on is the right one.
To support this growth, we’ve also invested in new state-of-the-art equipment for our laboratory. These upgrades will allow us to significantly increase our sample throughput and expand the scope of our internal validation work — a critical step as we prepare for the next phase of development and scale.
We remain energized by the mission and grounded in the science. While much of what we’re building is still under wraps, the momentum behind it is very real — and growing.
Stay tuned.
